UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2026

The United States non-alcoholic steatohepatitis (NASH) biomarker market is anticipated to register a CAGR of 20.70% over the forecast period. The country’s market growth is facilitated by the surging prevalence of non-alcoholic fatty liver disease and the increasing numbers of obese patients. The base year considered for the market study is 2020, and the forecast years are from 2021 to 2026.
united-states-non-alcoholic-steatohepatitis-biomarker-market

To learn more about this report, request a free sample copy

The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing annually, in the United States, and the trends also signify the condition’s increasing occurrence rate. Moreover, the disease is anticipated to become the most prevalent chronic liver condition across the country’s population. This is essentially accredited to the Type 2 diabetes and obesity epidemic in the United States. As a result, the likelihood of acquiring non-alcoholic steatohepatitis (NASH) is considerably increasing.

According to the 2018 estimations put forth by the NASH Education Program, the incidence of non-alcoholic steatohepatitis is projected to increase by 63%, from 2015 to 2030. The condition is also expected to become the leading cause of liver transplantation by 2020, across the United States. Currently, NASH is regarded as the second-most common indication of liver transplantation in the country, following chronic hepatitis C, as the condition’s prevalence continues to augment. Therefore, these factors play an important role in driving the market growth in the United States.

Gilead Sciences Inc, headquartered in the United States, is a biopharmaceutical company that develops, discovers, and commercializes therapeutics across areas of unmet medical needs within the United States, Europe, as well as internationally. It offers Yescarta, a chemical antigen receptor T-cell therapy, for adult patients with refractory or relapsed large B-cell lymphoma, and Letairis, an oral formulation of an endothelin receptor antagonist, for pulmonary hypertension, among others.

 

TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. SCOPE OF STUDY
    3. METHODOLOGY
    4. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. COUNTRY SNAPSHOT
    3. COUNTRY ANALYSIS
    4. KEY GROWTH ENABLERS
    5. KEY CHALLENGES
  3. KEY ANALYTICS
    1.    PORTER’S FIVE FORCES ANALYSIS
      1. THREAT OF NEW ENTRY
      2. THREAT OF SUBSTITUTION
      3. BUYER’S POWER
      4. SUPPLIER’S POWER
      5. COMPETITIVE RIVALRY
    2. IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
    3. OPPORTUNITY MATRIX
    4. VENDOR LANDSCAPE
    5. KEY INVESTMENT INSIGHTS
  4. MARKET BY TYPE
    1. SERUM BIOMARKER
    2. HEPATIC FIBROSIS BIOMARKER
    3. APOPTOSIS BIOMARKER
    4. OXIDATIVE STRESS BIOMARKER
    5. OTHER TYPES
  5. MARKET BY END-USER
    1. PHARMA & CRO INDUSTRY
    2. DIAGNOSTIC LAB
    3. ACADEMIC RESEARCH KEY
    4. HOSPITAL
  6. COMPETITIVE LANDSCAPE
    1.    KEY STRATEGIC DEVELOPMENTS
      1. MERGER & ACQUISITIONS
      2. PRODUCT LAUNCH & DEVELOPMENTS
      3. PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
      4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
    2.    COMPANY PROFILE
      1. BRISTOL-MYERS SQUIBB COMPANY
      2. GILEAD SCIENCES INC
      3. MADRIGAL PHARMACEUTICALS
      4. MERCK & CO
      5. PFIZER INC
LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER

TABLE 2: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 3: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, FORECAST YEARS, 2021-2026 (IN $ MILLION)

TABLE 4: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 5: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, FORECAST YEARS, 2021-2026 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, IN 2020

FIGURE 6: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY SERUM BIOMARKER, 2021-2026 (IN $ MILLION)

FIGURE 7: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HEPATIC FIBROSIS BIOMARKER, 2021-2026 (IN $ MILLION)

FIGURE 8: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY APOPTOSIS BIOMARKER, 2021-2026 (IN $ MILLION)

FIGURE 9: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OXIDATIVE STRESS BIOMARKER, 2021-2026 (IN $ MILLION)

FIGURE 10: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OTHER TYPES, 2021-2026 (IN $ MILLION)

FIGURE 11: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, IN 2020

FIGURE 12: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY PHARMA & CRO INDUSTRY, 2021-2026 (IN $ MILLION)

FIGURE 13: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY DIAGNOSTIC LAB, 2021-2026 (IN $ MILLION)

FIGURE 14: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY ACADEMIC RESEARCH KEY, 2021-2026 (IN $ MILLION)

FIGURE 15: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HOSPITAL, 2021-2026 (IN $ MILLION)

Request For A Free Sample